Management of dyslipidemia in patients with metabolic syndrome

Journal of the American Pharmacists Association : JAPhA
Mark J Cziraky

Abstract

To review the management of dyslipidemia in patients with metabolic syndrome. Medline search (2000-2002) conducted for English language articles using the search terms metabolic syndrome, impaired fasting glucose, glucose intolerance, and antilipemic agents; selective search for clinical trials of lipid therapy conducted in dialogue databases (1990-2002). In addition, current dyslipidemia treatment guidelines reviewed. By the author. By the author. The metabolic syndrome is increasingly recognized as a strong predictor of patient risk for developing coronary artery disease (CAD). It is associated with an atherogenic dyslipidemia characterized by elevated levels of triglycerides, reduced levels of high-density lipoprotein cholesterol (HDL-C) and a preponderance of small dense low-density lipoprotein (LDL) particles. Controlled clinical trials show similar or greater cardiovascular benefits from lipid-modifying therapies in patient subgroups with diabetes, impaired fasting glucose, and metabolic syndrome, compared with overall study populations. Current guidelines recommend intensified lipid management. Therapeutic lifestyle changes, with emphasis on weight loss, are particularly important for patients with metabolic syndrome. St...Continue Reading

References

Jan 27, 1975·JAMA : the Journal of the American Medical Association
Aug 8, 1990·JAMA : the Journal of the American Medical Association·A Garg, S M Grundy
Mar 2, 1994·JAMA : the Journal of the American Medical Association·J M McKenneyV M Chinchili
Nov 18, 1998·The American Journal of Cardiology·P O Kwiterovich
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jul 27, 1999·The American Journal of Cardiology·B V Howard
May 16, 2000·Journal of Internal Medicine·D GavishA Rubinstein
Jul 6, 2000·Circulation·UNKNOWN Bezafibrate Infarction Prevention (BIP) study
Aug 23, 2000·The Journal of Clinical Investigation·H N Ginsberg
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
May 26, 2001·The American Journal of Cardiology·R H Knopp
Jul 24, 2001·JAMA : the Journal of the American Medical Association·A D PradhanP M Ridker
Aug 4, 2001·The Annals of Pharmacotherapy·A Shek, M J Ferrill
Jan 5, 2002·The New England Journal of Medicine·B G BrownJ J Albers
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Earl S FordWilliam H Dietz
Jan 17, 2002·The New England Journal of Medicine·R S VasanD Levy
Feb 19, 2002·The Annals of Pharmacotherapy·Mohamed A Omar, James P Wilson
Aug 21, 2002·Circulation·Richard C PasternakUNKNOWN National Heart, Lung and Blood Institute
Dec 4, 2002·JAMA : the Journal of the American Medical Association·Hanna-Maaria LakkaJukka T Salonen
Dec 7, 2002·The American Journal of Cardiology·Michael H Davidson
Dec 28, 2002·Diabetes Care·Steven M Haffner, UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

May 26, 2005·Current Treatment Options in Cardiovascular Medicine·Prakash C Deedwania, Natalia Volkova
Nov 2, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Richard W Nesto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.